Joel Greenblatt's UTHR Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 80,018 shares of United Therapeutics Corporation (UTHR) worth $38.99 M, representing 0.14% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 51 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in UTHR, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2014, adding 329,577 shares. Largest reduction occurred in Q3 2014, reducing 357,665 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's United Therapeutics Corporation (UTHR) Holding Value Over Time
Track share changes against reported price movement
Quarterly United Therapeutics Corporation (UTHR) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -939 | Reduce 1.16% | 80,018 | $487.25 |
| Q3 2025 | -8,446 | Reduce 9.45% | 80,957 | $419.21 |
| Q2 2025 | +61 | Add 0.07% | 89,403 | $287.35 |
| Q1 2025 | +28,163 | Add 46.03% | 89,342 | $308.27 |
| Q4 2024 | +9,121 | Add 17.52% | 61,179 | $352.84 |
| Q3 2024 | +4,465 | Add 9.38% | 52,058 | $358.35 |
| Q2 2024 | +1,524 | Add 3.31% | 47,593 | $318.55 |
| Q1 2024 | +19,863 | Add 75.80% | 46,069 | $229.72 |
| Q4 2023 | -755 | Reduce 2.80% | 26,206 | $219.89 |
| Q3 2023 | -1,300 | Reduce 4.60% | 26,961 | $225.87 |
| Q2 2023 | -94 | Reduce 0.33% | 28,261 | $220.75 |
| Q1 2023 | +18,045 | Add 175.02% | 28,355 | $223.96 |
| Q4 2022 | -2,236 | Reduce 17.82% | 10,310 | $278.09 |
| Q3 2022 | +3,469 | Add 38.22% | 12,546 | $209.39 |
| Q2 2022 | +1,688 | Add 22.84% | 9,077 | $235.65 |
| Q1 2022 | -1,676 | Reduce 18.49% | 7,389 | $179.46 |
| Q4 2021 | -4,054 | Reduce 30.90% | 9,065 | $216.11 |
| Q3 2021 | +3,009 | Add 29.76% | 13,119 | $184.62 |
| Q2 2021 | -9,054 | Reduce 47.24% | 10,110 | $179.43 |
| Q1 2021 | +7,546 | Add 64.95% | 19,164 | $167.29 |
| Q4 2020 | -17,130 | Reduce 59.59% | 11,618 | $151.75 |
| Q3 2020 | -5,270 | Reduce 15.49% | 28,748 | $101.02 |
| Q2 2020 | +4,458 | Add 15.08% | 34,018 | $120.99 |
| Q1 2020 | -39,631 | Reduce 57.28% | 29,560 | $94.82 |
| Q4 2019 | +21,574 | Add 45.31% | 69,191 | $88.08 |
| Q3 2019 | -596 | Reduce 1.24% | 47,617 | $79.72 |
| Q2 2019 | +35,858 | Add 290.23% | 48,213 | $78.07 |
| Q1 2019 | -18,572 | Reduce 60.05% | 12,355 | $117.36 |
| Q4 2018 | -4,081 | Reduce 11.66% | 30,927 | $108.90 |
| Q3 2018 | -32,233 | Reduce 47.94% | 35,008 | $127.89 |
| Q2 2018 | -14,519 | Reduce 17.76% | 67,241 | $113.15 |
| Q1 2018 | +15,490 | Add 23.37% | 81,760 | $112.37 |
| Q4 2017 | -114,915 | Reduce 63.42% | 66,270 | $147.96 |
| Q3 2017 | -12,805 | Reduce 6.60% | 181,185 | $117.19 |
| Q2 2017 | -15,150 | Reduce 7.24% | 193,990 | $129.73 |
| Q1 2017 | +43,115 | Add 25.97% | 209,140 | $135.38 |
| Q4 2016 | -151,333 | Reduce 47.69% | 166,025 | $143.43 |
| Q3 2016 | -49,717 | Reduce 13.54% | 317,358 | $118.08 |
| Q2 2016 | +4,510 | Add 1.24% | 367,075 | $105.92 |
| Q1 2016 | +34,255 | Add 10.43% | 362,565 | $111.43 |
| Q4 2015 | +27,105 | Add 9.00% | 328,310 | $156.61 |
| Q3 2015 | +40,080 | Add 15.35% | 301,205 | $131.24 |
| Q2 2015 | -29,952 | Reduce 10.29% | 261,125 | $173.95 |
| Q1 2015 | -32,011 | Reduce 9.91% | 291,077 | $172.44 |
| Q4 2014 | +34,687 | Add 12.03% | 323,088 | $129.49 |
| Q3 2014 | -357,665 | Reduce 55.36% | 288,401 | $128.65 |
| Q2 2014 | +329,577 | Add 104.14% | 646,066 | $88.49 |
| Q1 2014 | +121,894 | Add 62.64% | 316,489 | $94.03 |
| Q4 2013 | -177,552 | Reduce 47.71% | 194,595 | $113.08 |
| Q3 2013 | +30,817 | Add 9.03% | 372,147 | $78.85 |
| Q2 2013 | +341,330 | Add 0.00% | 341,330 | $65.82 |
Joel Greenblatt's United Therapeutics Corporation Investment FAQs
Joel Greenblatt first purchased United Therapeutics Corporation (UTHR) in Q2 2013, acquiring 341,330 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held United Therapeutics Corporation (UTHR) for 51 quarters since Q2 2013.
Joel Greenblatt's largest addition to United Therapeutics Corporation (UTHR) was in Q2 2013, adding 341,330 shares worth $22.47 M.
According to the latest 13F filing for Q4 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 80,018 shares of United Therapeutics Corporation (UTHR), valued at approximately $38.99 M.
As of the Q4 2025 filing, United Therapeutics Corporation (UTHR) represents approximately 0.14% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in United Therapeutics Corporation (UTHR) was 646,066 shares, as reported at the end of Q2 2014.